Pfizer (NYSE:PFE) Shares Up 1.3% – What’s Next?

Pfizer Inc. (NYSE:PFE)’s stock price shot up 1.3% during mid-day trading on Friday . The company traded as high as $27.30 and last traded at $27.0060. 42,190,331 shares changed hands during mid-day trading, a decline of 2% from the average session volume of 43,142,543 shares. The stock had previously closed at $26.67.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Seagen acquisition beginning to pay off — coverage notes Pfizer’s $43B Seagen deal is giving it a dominant position in the Antibody‑Drug Conjugate (ADC) market, strengthening its oncology growth runway beyond legacy products. This supports longer‑term revenue diversification. Pfizer Inc. (PFE): One of the Best Safe Stocks to Invest in for Beginners
• Positive Sentiment: Dividend reaffirmed — Pfizer’s board declared a $0.43 quarterly dividend (payable June 12; record date May 8). The steady, high yield (roughly in the mid‑single digits) supports income investor demand and can act as a valuation floor. Pfizer Declares Second-Quarter 2026 Dividend
• Positive Sentiment: Pipeline progress and obesity/GLP‑1 push — Pfizer reported Phase 2b results and is advancing a monthly GLP‑1 obesity program (PF‑08653944) and several early‑stage studies (heart failure, liver, new Phase 1 cancer trial), adding meaningful optionality to future growth. Pfizer’s Monthly GLP-1 Push Tests Balance Between Obesity Growth And Dividends
• Neutral Sentiment: Shareholder meeting results released — Pfizer posted 2026 shareholder meeting outcomes; no major governance surprises were reported, so minimal immediate market impact. Pfizer Unveils 2026 Shareholder Meeting Results
• Neutral Sentiment: Eliquis distribution move — Pfizer and Bristol Myers will make Eliquis available through Mark Cuban’s Cost Plus pharmacy starting April 27, which may expand access and volume but could compress pricing/margins; likely mixed to neutral near‑term. Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban’s online pharmacy
• Negative Sentiment: Trial termination trims oncology pipeline — Pfizer ended an early‑stage cancer trial, signaling a pullback for that specific program and reducing near‑term upside from that asset. This is a discrete negative for pipeline expectations. Pfizer Ends Early-Stage Cancer Trial, Trimming Its Oncology Pipeline
• Negative Sentiment: Analyst skepticism and sell ratings persist — Barclays reiterated a sell and some coverage favors peers (e.g., Merck) on valuation and dividend tradeoffs, which can cap multiple expansion and weigh on sentiment. Barclays Remains a Sell on Pfizer (PFE)

Analyst Ratings Changes

A number of brokerages have issued reports on PFE. Morgan Stanley raised their price target on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Bank of America decreased their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. HSBC raised their price target on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Royal Bank Of Canada reaffirmed an “underperform” rating and issued a $25.00 price objective on shares of Pfizer in a research note on Monday. Finally, UBS Group lifted their price objective on Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a research note on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $28.48.

Pfizer Stock Up 1.3%

The firm has a market capitalization of $153.56 billion, a price-to-earnings ratio of 19.86 and a beta of 0.43. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The firm has a 50 day moving average price of $27.24 and a two-hundred day moving average price of $26.06.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company’s revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.63 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.4%. Pfizer’s payout ratio is 126.47%.

Hedge Funds Weigh In On Pfizer

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Y Intercept Hong Kong Ltd purchased a new stake in Pfizer during the 3rd quarter worth approximately $3,019,000. Money Concepts Capital Corp increased its holdings in Pfizer by 29.9% during the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after purchasing an additional 57,188 shares during the last quarter. Vista Investment Partners LLC increased its holdings in Pfizer by 236.1% during the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after purchasing an additional 48,900 shares during the last quarter. Kepler Cheuvreux Suisse SA purchased a new stake in Pfizer during the 3rd quarter worth approximately $16,613,000. Finally, Fort Washington Investment Advisors Inc. OH increased its holdings in Pfizer by 11.2% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,892,663 shares of the biopharmaceutical company’s stock worth $48,225,000 after purchasing an additional 190,946 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.